Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > Alex seems pumped on ACST

<< Previous

Bullboard Posts

Next >>

Comment by hipfneron Dec 03, 2019 8:56am

197 Views

Post# 30416484

RE:RE:RE:RE:Alex seems pumped on ACST

I've held this for years. Frankly I had no appreciation of how long a process it was to go from idea to Phase 3. Now that is nearly over and I also anticipate (yet another) successful trial. Then another set of results in early 2020. Then eventual govt. approval.

I am hoping that a bidding war starts soon as Acasti is totally unprepared to commercialize the drug and market it. There have been far too many money-raises, we don't need another.

<< Previous

Bullboard Posts

Next >>

Mid-year review: How has gold been performing?